













Catherine Knupp | Zoetis | Zoetis 




























 







Zoetis.com uses cookies to improve your experience when browsing our website. By continuing to use this site, you are agreeing to their use. To find out more, view our cookie policy. 


Agree











































About UsZoetis at a Glance
Vision & Mission
Core Beliefs
Awards & Recognition
History
Zoetis Executive TeamBoard Committees & Charters
Board of Directors
Contact Our Directors

Corporate GovernancePolicies & Procedures
Board Committees & Charters
Board of Directors
Contact Our Directors

Corporate Compliance
Company Locations







Home / About Us / Zoetis Executive Team / ZOETIS EXECUTIVE TEAM 



Share
Share on twitter
Share on facebook
Share on linkedin
Share on google_plusone_share
Share on email





Print





Text Size







< Prev
Next >



ZOETIS EXECUTIVE TEAM


Catherine Knupp




Executive Vice President and President, Research and Development






Dr. Cathy Knupp is executive vice president and president of Research and Development at Zoetis. Prior to that, Dr. Knupp served as vice president, Veterinary Medicine Research and Development at Pfizer Animal Health, a position she held since 2005. In her role, she is responsible for managing global R&D activities in support of discovering and registering medicines and vaccines to prevent disease in companion animals and livestock species, and improve health and optimize performance.
Prior to joining Pfizer Animal Health, Dr. Knupp led Pfizer's Michigan laboratories in pharmacokinetics, dynamics and metabolism, and chaired the Midwest Exploratory Development Management Team in Pfizer Global Research and Development.
She began her career in 1987 at Bristol-Myers Squibb where she held positions of increasing responsibility in drug metabolism and pharmacokinetics. This experience led to her appointment as executive director, Drug Metabolism and Pharmacokinetics. Her last position with that company was as vice president, Chemical Manufacturing Controls (CMC), where she was responsible for global CMC regulatory submissions.
Dr. Knupp earned her Doctor of Veterinary Medicine (DVM) degree in 1985 from the University of Illinois, where she also received a master's degree in toxicology and a bachelor's degree in veterinary biosciences. She also earned another bachelor's degree in chemistry from Western Illinois University.










About Us
See Zoetis at a glance.More











                Select a Country

zoetis.com
zoetisZO.com



Argentina
Australia
Austria
Belgium (French)
Belgium (Dutch)
Brazil
Bolivia
Bulgaria
Canada
Chile
China
Colombia
Costa Rica
Croatia
Czech Republic
Ecuador
Egypt
Estonia
Finland
France
Germany
Greece
Hungary
India
Indonesia
Ireland
Israel
Italy
Japan
Latvia
Lithuania
Malaysia
Mexico
Morocco
Netherlands
New Zealand
Paraguay
Peru
Philippines
Poland
Portugal
Romania
Russia
Serbia
Slovakia
Slovenia
South Africa
South Korea
Spain
Switzerland
Taiwan
Thailand
Turkey
Ukraine
United Kingdom
United States
Uruguay
Vietnam
 You are leaving the country website to access another site in the group.
Regulatory constraints and medical practices vary from country to country. Consequently, the information provided on the site in which you enter may not be suitable for use in your country. 






Home

|Sitemap

|Privacy Policy

|Cookie Policy

|Terms of Use




















Catherine Knupp | Zoetis | Zoetis 




























 







Zoetis.com uses cookies to improve your experience when browsing our website. By continuing to use this site, you are agreeing to their use. To find out more, view our cookie policy. 


Agree











































About UsZoetis at a Glance
Vision & Mission
Core Beliefs
Awards & Recognition
History
Zoetis Executive TeamBoard Committees & Charters
Board of Directors
Contact Our Directors

Corporate GovernancePolicies & Procedures
Board Committees & Charters
Board of Directors
Contact Our Directors

Corporate Compliance
Company Locations







Home / About Us / Zoetis Executive Team / ZOETIS EXECUTIVE TEAM 



Share
Share on twitter
Share on facebook
Share on linkedin
Share on google_plusone_share
Share on email





Print





Text Size







< Prev
Next >



ZOETIS EXECUTIVE TEAM


Catherine Knupp




Executive Vice President and President, Research and Development






Dr. Cathy Knupp is executive vice president and president of Research and Development at Zoetis. Prior to that, Dr. Knupp served as vice president, Veterinary Medicine Research and Development at Pfizer Animal Health, a position she held since 2005. In her role, she is responsible for managing global R&D activities in support of discovering and registering medicines and vaccines to prevent disease in companion animals and livestock species, and improve health and optimize performance.
Prior to joining Pfizer Animal Health, Dr. Knupp led Pfizer's Michigan laboratories in pharmacokinetics, dynamics and metabolism, and chaired the Midwest Exploratory Development Management Team in Pfizer Global Research and Development.
She began her career in 1987 at Bristol-Myers Squibb where she held positions of increasing responsibility in drug metabolism and pharmacokinetics. This experience led to her appointment as executive director, Drug Metabolism and Pharmacokinetics. Her last position with that company was as vice president, Chemical Manufacturing Controls (CMC), where she was responsible for global CMC regulatory submissions.
Dr. Knupp earned her Doctor of Veterinary Medicine (DVM) degree in 1985 from the University of Illinois, where she also received a master's degree in toxicology and a bachelor's degree in veterinary biosciences. She also earned another bachelor's degree in chemistry from Western Illinois University.










About Us
See Zoetis at a glance.More











                Select a Country

zoetis.com
zoetisZO.com



Argentina
Australia
Austria
Belgium (French)
Belgium (Dutch)
Brazil
Bolivia
Bulgaria
Canada
Chile
China
Colombia
Costa Rica
Croatia
Czech Republic
Ecuador
Egypt
Estonia
Finland
France
Germany
Greece
Hungary
India
Indonesia
Ireland
Israel
Italy
Japan
Latvia
Lithuania
Malaysia
Mexico
Morocco
Netherlands
New Zealand
Paraguay
Peru
Philippines
Poland
Portugal
Romania
Russia
Serbia
Slovakia
Slovenia
South Africa
South Korea
Spain
Switzerland
Taiwan
Thailand
Turkey
Ukraine
United Kingdom
United States
Uruguay
Vietnam
 You are leaving the country website to access another site in the group.
Regulatory constraints and medical practices vary from country to country. Consequently, the information provided on the site in which you enter may not be suitable for use in your country. 






Home

|Sitemap

|Privacy Policy

|Cookie Policy

|Terms of Use






 












Catherine Knupp, Zoetis Inc. EVP & President, Research & Development - REDBOOKS








































Brands, Marketers, Agencies. Search Less. Sell More.





/   SIGN IN

GET A FREE TRIAL   
CONTACT US: (800) 908-5395





















Catherine  Knupp
EVP & President, Research & Development, Zoetis Inc.

EMAIL: 
                      







              Real-time sales trigger feed - generated by REDBOOKS machine learning and natural language processing technology, tracking 800,000+ news sources to aggregate all new executives, job/role changes and news on decision makers, brands and agencies in the media/marketing industry.
              

              This sales feed is for Catherine  Knupp at Zoetis Inc.. Catherine  Knupp works as EVP & President, Research & Development , acting in a Executive Management role .  Zoetis Inc. is a leader in Pharmaceuticals & Health Care Products .
              REDBOOKS tracks personnel changes for advertisers spending over $1 million annually.
              

              For more Executive Management leads or media/marketing prospecting automation, start a free trial now.
              

Recent Related News


05/09/2017:


Zoetis Receives European Commission Marketing Authorization for Cytopoint® lokivetmab

..... "We are honored to be granted the first approval of a monoclonal antibody therapy for veterinary use by the European Commission," said Dr. Catherine Knupp, Executive Vice President and President, Research and Development at Zoetis. "As the first such therapy to provide relief from atopic dermatitis, we are once again using our science and focus on our customers' most pressing challenges to find solutions for an area of unmet need in animal health......

People In This Article:
Catherine Knupp
 

05/02/2017:


First veterinary monoclonal antibody receives EU approval

..... Manufactured by Zoetis, the antibody targets and neutralises canine interleukin-31 (cIL-31), a key protein involved in triggering itch in dogs.
“We are honoured to be granted the first approval of a monoclonal antibody therapy for veterinary use by the European Commission,” said Dr Catherine Knupp, executive vice president and president, research and development at Zoetis.
“As the first such therapy to provide relief from atopic dermatitis, we are once again using our science and focus on our customers’ most pressing challenges to find solutions for an area of unmet need in animal health......

People In This Article:
Catherine Knupp
 






Learn more about Catherine  Knupp  and 260,000+ key contacts

  Create targeted lead lists

  Gain insider knowledge with advanced machine  learning
  Real-time verified contact info



Enter Work Email:

Please enter email address.
 Please enter valid email address.









             Learn more about Catherine  Knupp and 260,000+ key contacts
            



























First Name *

 Please enter first name.




Last Name *

 Please enter last name.






Company Name *

 Please enter company name.






Email *





Phone *

 Please enter phone number.
 Please enter 10 digits number.





What industry are you in? *  
                (Please select one the categories below)
Please enter value for the industry.




                     Media Sales
                  




                     Production
                  




                     Ad-Tech/Mar-Tech
                  




                     Sponsorship Sales
                  



  Agency New Business
                  



  Other:
                  




What is your role? *
                 
                 (Please select one the categories below)
Please enter value for the role.



  C-Suite
                  



  VP/Manager
                  



  Sales Rep
                  



  Other:
                  














Thank you for registering for a Free REDBOOKS.com Trial!
We are processing your request and will be in touch shortly to get you started!
For Immediate Assistance, please call us at (800) 908-5395 or email us at info@redbooks.com


























Home
Learn More
FREE Trial


Features




AD THINK Events
Thought Leadership Events
Top Advertiser Directory
Top Agency Directory



Add Your Agency
Update Your Agency
Agency Showcase
Advertising Associations
Creative Spotlight
Services and Suppliers


About Us
Blog
Contact Us
Jobs
Terms & Conditions
Privacy Policy





Customer Support
(800) 908-5395
Connect with us




















Copyright © 2017 Red Books LLC. All rights reserved





























    Catherine Knupp | Zoetis Inc | ZoomInfo.com






Catherine A. Knupp of Zoetis Inc Executive Profile

















 












Welcome!















Company News
Company Site
Premium
Log In


 



















Membership
Home
Portfolio
Stocks
Bonds
Funds
ETFs
CEF
Markets
Tools
Real Life Finance
Discuss





Investing Ideas


Fund Analyst Picks
Picks by Category
Fund Pick Performance
Picks & Pans E-Newsletter
Fund Spy Column
Fund Spy Book
Bond Squad
Fund Video Reports
FundInvestor Newsletter
ETF Investing
Fund Family Experts



Fund Reports


All Fund Analyst Reports
Fund Stewardship Reports



Fund Ratings


Highest-Rated Value
Highest-Rated Growth
Highest-Rated Large-Cap
Highest-Rated Mid-Cap
Highest-Rated Small-Cap
Foreign Fund Standouts
Star Rating Performance
Rating Methodology



Fund Performance


Top 1-Month Performers
Top YTD Performers
Top 1-Year Performers
Top 3-Year Performers
Top 5-Year Performers
Fund Category Returns
Biggest Daily NAV Changes
Closed-End Funds
Exchange-Traded Funds
Quarterly Market Outlook



Fund Screeners


Basic Screeners
Fund Screener
Long-Term Winners
Solid Small-Growth Funds
Conservative Bond Funds

Premium Screeners
Premium Fund Screener
Index Funds
Hidden Gems
Lower-Risk Foreign Funds


Video Center
 
 

 



 



Zoetis Inc
 ZTS


Add to PortfolioGet E-mail AlertsPrint This PagePDF ReportData QuestionQuoteChartStock AnalysisPerformanceKey RatiosFinancialsValuationInsidersOwnershipFilingsBondsOverviewExecutive CompensationInsider ActivityKey ExecutivesBoard of DirectorsCommittees
 


Key Executives
                > Catherine A. Knupp
            
Catherine A. Knupp, Executive Vice President and President, Research and Development



Profile
Connections






Biography



    Dr. Knupp has served as our Executive Vice President and President of Research and Development since October 2012 and was Vice President of Pfizer's Veterinary Medicine Research and Development business unit from 2005 to 2012. Dr. Knupp joined Pfizer in July 2001 and held various positions, including Vice President of Pfizer's Michigan laboratories for Pharmacokinetics, Dynamics and Metabolism.
    





Board Membership




Catherine A. Knupp is not a member of any boards




 


  







We value your feedback. Let us know what you think.













 


Site Directory
Site Map
Our Products












 



 



 




Corrections
Help
Advertising Opportunities
Licensing Opportunities
Glossary
RSS
Mobile Portfolio
Affiliate
Careers 
 


International Sites:
        	Australia
Canada
China
France
Germany
Hong Kong
Italy
The Netherlands
Norway
Spain
U.K.
Switzerland

 




Stocks by:
            Name
|
Ticker
|
Star Rating
|
Market Cap
|
Stock Type
|
Sector
|
Industry



Mutual Funds by:
            Star Rating
|
Investment Style
|
Total Assets
|
Category
|
Top Holdings
|
Top Sectors
|
Symbol / Ticker
|
Name



ETFs by:
            Star Rating
|
Category
|
Total Assets
|
Symbol / Ticker
|
Name



Articles by:
            Title
|
Date
|
Author
|
Collection
|
Interest
|
Popularity



Investment Categories by:
            Topic
|
Sector
|
Key Indicators
|
User Interest
|
Market Cap
|
Industry



Premium Stocks by:
            Name
|
Ticker
|
Star Rating
|
Market Cap
|
Stock Type
|
Sector
|
Industry



Premium Mutual Funds by:
            Star Rating
|
Investment Style
|
Total Assets
|
Category
|
Top Holdings
|
Top Sectors
|
Symbol / Ticker
|
Name



Premium ETFs by:
            Star Rating
|
Category
|
Total Assets
|
Symbol / Ticker
|
Name



Popular Articles by:
            Title
|
Date
|
Author
|
Collection
|
Interest
|
Popularity



Popular Investment Categories by:
            Topic
|
Sector
|
Key Indicators
|
User Interest
|
Market Cap
|
Industry




Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.
        © Copyright  Morningstar, Inc. All rights reserved. Please read our Terms of Useand Privacy Policy.Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time. Russell 2000 quote is 10 minutes delayed.
 


 
















Catherine Knupp 的个人主页 | Facebook


Facebook邮箱或手机号密码忘记帐户？中文(简体)English (US)日本語한국어Français (France)Bahasa IndonesiaPolskiEspañolPortuguês (Brasil)DeutschItalianoMessengerFacebook Lite用户地点游戏位置名人二手市场小组食谱彩色气球Instagram公司简介创建广告创建主页开发者招聘信息隐私权政策Cookie广告选项条款设置活动日志 Facebook © 2017
















 







Zoetis Inc. (NYSE:ZTS) Shares Sold by Boussard & Gavaudan Investment Management LLP | Daily Political











































































Home
About/Contact
Columnists
Privacy Policy
























Headlines
Politics
Nation
World
Issues
Economy
Finance




















Zoetis Inc. - Get News & Ratings Daily

		Enter your email address below to get the latest news and analysts' ratings for Zoetis Inc. with our FREE daily email newsletter:



 






Follow DailyPolitical

 
 










Latest News



Saga Communications, Inc. (NYSEMKT:SGA) Downgraded by ValuEngine					

VALE S.A. (NYSE:VALE) Earns “Hold” Rating from Jefferies Group LLC					

Mastercard Incorporated (NYSE:MA) Price Target Raised to $0.00					

United Bank Inc. Boosts Stake in HollyFrontier Corporation (NYSE:HFC)					

Healthcare Services Group, Inc. (NASDAQ:HCSG) Raised to “Buy” at Zacks Investment Research					

Zoetis Inc. (NYSE:ZTS) Shares Sold by Boussard & Gavaudan Investment Management LLP					

TRI Pointe Group, Inc. (NYSE:TPH) to Post Q4 2017 Earnings of $0.57 Per Share, Wedbush Forecasts					

Senseonics Holdings Inc (NYSE:SENS) Sees Large Decrease in Short Interest					

Stifel Nicolaus Reaffirms Buy Rating for Tallgrass Energy GP, LP (NYSE:TEGP)					

Erin Energy Corp (NYSE:ERN) Sees Significant Drop in Short Interest					

Teva Pharmaceutical Industries Limited’s (NYSE:TEVA) Outperform Rating Reaffirmed at Oppenheimer Holdings, Inc.					

United Bank Inc. Holds Stake in National Fuel Gas Company (NFG)					

Trilogy Metals Inc (NYSE:TMQ) Short Interest Down 8.6% in June					

Target Corporation (NYSE:TGT) Downgraded by Vetr Inc.					

Boussard & Gavaudan Investment Management LLP Has $31.35 Million Position in Tiffany & Co. (NYSE:TIF)					

Hi-Crush Partners LP (NYSE:HCLP) Given Average Rating of “Buy” by Analysts					

Compass Diversified Holdings (NYSE:CODI) Earns Buy Rating from Jefferies Group LLC					

Aberdeen Asset Management plc (LON:ADN) Lifted to Buy at HSBC Holdings plc					

Mandatum Life Insurance Co Ltd Sells 1,411 Shares of McCormick & Company, Incorporated (NYSE:MKC)					

CA Inc. (NASDAQ:CA) Stake Maintained by Mandatum Life Insurance Co Ltd					





 





						Zoetis Inc. (NYSE:ZTS) Shares Sold by Boussard & Gavaudan Investment Management LLP					

						 July 18th, 2017  - 0 comments - Filed Under -
 by Latisha Jones 


							Filed Under: Finance - SEC Filing Articles 







Tweet










Boussard & Gavaudan Investment Management LLP reduced its position in  Zoetis Inc. (NYSE:ZTS) by 63.5% during the second quarter, Holdings Channel reports. The institutional investor  owned 20,398 shares of the company’s stock after selling 35,446 shares during the period. Zoetis comprises about  0.1% of Boussard & Gavaudan Investment Management LLP’s holdings, making the stock its 14th largest position. Boussard & Gavaudan Investment Management LLP’s holdings in Zoetis were worth $1,278,000 as of its most recent filing with the SEC. 
Other institutional investors have also bought and sold shares of the company. Dixon Hubard Feinour & Brown Inc. VA raised its position in shares of  Zoetis by 2.8% in the second quarter. Dixon Hubard Feinour & Brown Inc. VA now owns 12,265 shares of the company’s stock valued at $765,000 after buying an additional 330 shares during the period.  Ardevora Asset Management LLP purchased a new position in shares of  Zoetis during the second quarter valued at about $28,801,000.  CENTRAL TRUST Co raised its position in shares of  Zoetis by 640.5% in the second quarter. CENTRAL TRUST Co now owns 19,728 shares of the company’s stock valued at $1,231,000 after buying an additional 17,064 shares during the period.  OLD National Bancorp IN purchased a new position in shares of  Zoetis during the second quarter valued at about $1,614,000.  Finally, Eqis Capital Management Inc. purchased a new position in shares of  Zoetis during the second quarter valued at about $352,000. 95.10% of the stock is currently owned by institutional investors. 
Shares of Zoetis Inc. (NYSE ZTS) traded down 1.08% during midday trading on Tuesday, hitting $62.39. The company’s stock had a trading volume of 420,870 shares. The company has a 50-day moving average price of $62.00 and a 200 day moving average price of $56.13. The company has a market cap of $30.62 billion, a P/E ratio of 36.27 and a beta of 1.03. Zoetis Inc. has a 1-year low of $46.86 and a 1-year high of $63.85. 




Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, May 4th. The company reported $0.53 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.05. Zoetis had a return on equity of 65.35% and a net margin of 17.25%. The business had revenue of $1.23 billion during the quarter, compared to analyst estimates of $1.20 billion. During the same period in the previous year, the company posted $0.48 EPS. The firm’s revenue was up 5.9% compared to the same quarter last year.  On average, equities research analysts predict that  Zoetis Inc. will post $2.33 EPS for the current year. 
The company also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Investors of record on Thursday, June 15th will be given a $0.105 dividend. This represents a $0.42 dividend on an annualized basis and a yield of 0.67%. The ex-dividend date is Tuesday, June 13th. Zoetis’s payout ratio is 24.42%. 
COPYRIGHT VIOLATION NOTICE: This news story was first  posted by Daily Political and is owned by of Daily Political. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://www.dailypolitical.com/2017/07/18/zoetis-inc-nysezts-shares-sold-by-boussard-gavaudan-investment-management-llp.html. 
ZTS has been the topic of several research reports. Zacks Investment Research raised Zoetis from a “hold” rating to a “buy” rating and set a $67.00 price target on the stock in a research note on Wednesday, May 10th. Jefferies Group LLC upped their price target on Zoetis from $65.00 to $70.00 and gave the company a “buy” rating in a research note on Tuesday, May 9th. BMO Capital Markets  reaffirmed a “buy” rating and set a $60.00 price target on shares of Zoetis in a research note on Thursday, May 4th. Argus  reaffirmed a “buy” rating and set a $69.00 price target (up previously from $60.00) on shares of Zoetis in a research note on Tuesday, May 30th. Finally, CL King initiated coverage on Zoetis in a research note on Friday, May 26th. They set a “buy” rating and a $71.00 price target on the stock. One equities research analyst  has rated the stock with a sell rating, five have issued  a hold rating and thirteen have given a buy rating to the company. Zoetis  has an average rating of “Buy” and a consensus target price of $63.11.
In related news, insider Catherine A. Knupp sold 5,785 shares of the business’s stock in a transaction dated Friday, May 12th. The stock was sold at an average price of $60.16, for a total value of $348,025.60. Following the completion of the sale, the insider now directly owns 24,415 shares of the company’s stock, valued at approximately $1,468,806.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own  0.31% of the company’s stock. 
About Zoetis
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).






Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



 
















 Comment on this Post

Click here to cancel reply.



Name (required)

Mail (will not be published) (required)

Website






Wordpress Hashcash needs javascript to work, but your browser has javascript disabled. Your comment will be deleted!




Latest News




Jeff Sessions Spoke of Resigning After Tensions Increase with Trump





President Trump’s Tweets Complicate Already Complicated Week





World Leaders Very Critical of Paris Agreement Decision by Trump





Aide to President Trump Resigns With More Expected





Scud-Class Missile Launched by North Korea














			© DailyPolitical, LLC 2009-2017. All rights reserved. 


Privacy Policy |
			About | Columnists 
			| Contact 



























































Insider Trading - Knupp Catherine A. - Form 4 SEC Filings












Home |
Archives |
Products |
About |
Contact |
FAQ |



New User?
Sign Up | 
Sign In









Form 4 Filings


Insider Buys


Significant Buys


Penny StocksInsider Buying


Insider Sales




Insider Buy Sell Ratios


Stock Options


Insider TradingStock Screener


Insider TradingGraph View


Insider Watch





Sec Filings Insider Trading - Knupp Catherine A.





Select Time period: 
1 Month
2 Months
3 Months
6 Months
1 Year
2 Years
3 Years
4 Years
All Data
 

     



google

   



yahoo!



Send this page to:  

Blog
  



Digg

  



Reddit

  



Facebook

  



Stumble

  



del.icio.us








Enter Stock Ticker Symbol or Cik:




Cik Lookup...






Search By Company or Insider Name:







"Insiders might sell their shares for any number of reasons, but they buy them for only one:
they think the price will rise"
- Peter Lynch ==>>

What is insider trading>>



Email a friend >>...







Historical filings delayed by 6 months. New user?
Sign Up for real time data.
Existing user?
Sign In

Stock options: Exercise, Award, Grant, Conversion



TransactionDate
ReportedDate
ExercisableExpiration
Company
Symnbol
InsiderRelationship
SharesTraded
ConversionPrice
SharesOwned
Filing




2016-10-14Option Award
2016-10-179:43 pm
N/AN/A
Zoetis Inc.
ZTS
Knupp Catherine A.Executive Vice President
444
$16.06
11,355(Direct)
View


2016-08-15Exercise
2016-08-174:13 pm
N/AN/A
Zoetis Inc.
ZTS
Knupp Catherine A.Executive Vice President
6,430
$0
28,497(Direct)
View


2016-08-15Tax Withholding
2016-08-174:13 pm
N/AN/A
Zoetis Inc.
ZTS
Knupp Catherine A.Executive Vice President
2,614
$52.38
28,497(Direct)
View


2016-08-15Exercise
2016-08-174:13 pm
N/AN/A
Zoetis Inc.
ZTS
Knupp Catherine A.Executive Vice President
6,431
$0
28,497(Direct)
View


2016-07-19Option Award
2016-07-204:03 pm
N/AN/A
Zoetis Inc.
ZTS
Knupp Catherine A.Executive Vice President
382
$15.91
10,911(Direct)
View


2016-04-15Option Award
2016-04-195:09 pm
N/AN/A
Zoetis Inc.
ZTS
Knupp Catherine A.Executive Vice President
764
$15.4
10,528(Direct)
View


2016-03-03Option Award
2016-03-044:20 pm
N/AN/A
Zoetis Inc.
ZTS
Knupp Catherine A.Executive Vice President
2,219
$13.22
9,765(Direct)
View


2016-02-19Option Award
2016-02-234:32 pm
N/AN/A
Zoetis Inc.
ZTS
Knupp Catherine A.Executive Vice President
8,765
$41.83
150,942(Direct)
View


2016-02-19Option Award
2016-02-234:32 pm
N/AN/A
Zoetis Inc.
ZTS
Knupp Catherine A.Executive Vice President
32,767
$0
150,942(Direct)
View


2016-02-01Exercise
2016-02-037:24 pm
N/AN/A
Zoetis Inc.
ZTS
Knupp Catherine A.Executive Vice President
11,820
$0
26,023(Direct)
View


2016-02-01Tax Withholding
2016-02-037:24 pm
N/AN/A
Zoetis Inc.
ZTS
Knupp Catherine A.Executive Vice President
3,537
$42.96
26,023(Direct)
View


2016-02-01Exercise
2016-02-037:24 pm
N/AN/A
Zoetis Inc.
ZTS
Knupp Catherine A.Executive Vice President
11,820
$0
26,023(Direct)
View


2016-01-13Option Award
2016-01-144:32 pm
N/AN/A
Zoetis Inc.
ZTS
Knupp Catherine A.Executive Vice President
460
$13.85
7,546(Direct)
View


2015-12-31Exercise
2016-01-054:32 pm
N/AN/A
Zoetis Inc.
ZTS
Knupp Catherine A.Executive Vice President
9,865
$0
37,760(Direct)
View


2015-12-31Tax Withholding
2016-01-054:32 pm
N/AN/A
Zoetis Inc.
ZTS
Knupp Catherine A.Executive Vice President
4,080
$47.92
37,760(Direct)
View


2015-12-31Exercise
2016-01-054:32 pm
N/AN/A
Zoetis Inc.
ZTS
Knupp Catherine A.Executive Vice President
9,866
$0
37,760(Direct)
View


2015-10-13Option Award
2015-10-144:30 pm
N/AN/A
Zoetis Inc.
ZTS
Knupp Catherine A.Executive Vice President
471
$13.54
7,085(Direct)
View


2015-07-09Option Award
2015-07-104:04 pm
N/AN/A
Zoetis Inc.
ZTS
Knupp Catherine A.Executive Vice President
431
$14.79
6,614(Direct)
View


2015-04-09Option Award
2015-04-1009:28 am
N/AN/A
Zoetis Inc.
ZTS
Knupp Catherine A.Executive Vice President
691
$14.78
6,183(Direct)
View


2015-03-05Option Award
2015-03-0909:27 am
N/AN/A
Zoetis Inc.
ZTS
Knupp Catherine A.Executive Vice President
440
$9.46
5,493(Direct)
View


2015-03-05Option Award
2015-03-0909:27 am
N/AN/A
Zoetis Inc.
ZTS
Knupp Catherine A.Executive Vice President
1,299
$14.52
5,493(Direct)
View


2015-02-27Option Award
2015-03-0308:42 am
N/AN/A
Zoetis Inc.
ZTS
Knupp Catherine A.Executive Vice President
7,232
$46.09
118,175(Direct)
View


2015-02-27Option Award
2015-03-0308:42 am
N/AN/A
Zoetis Inc.
ZTS
Knupp Catherine A.Executive Vice President
28,563
$0
118,175(Direct)
View


2015-02-23Exercise
2015-02-244:42 pm
N/AN/A
Zoetis Inc.
ZTS
Knupp Catherine A.Executive Vice President
3,213
$0
40,139(Direct)
View


2015-02-23Tax Withholding
2015-02-244:42 pm
N/AN/A
Zoetis Inc.
ZTS
Knupp Catherine A.Executive Vice President
1,354
$45.58
40,139(Direct)
View


2015-02-23Exercise
2015-02-244:42 pm
N/AN/A
Zoetis Inc.
ZTS
Knupp Catherine A.Executive Vice President
3,214
$0
40,139(Direct)
View









    © 2005-2017 SecForm4.Com All rights reserved.
    Archives:
    2017 2016 2015 2014 2013 2012 ... 
    Tue, 25 Jul 2017 08:12:51 -0500
  

    SEC is the U.S. Securities and Exchange Commission. EDGAR is a trademark of the SEC.
    SecForm4.Com is not affiliated with or approved by the U.S. Securities and Exchange Commission (SEC).
Terms of Use |
    Privacy Statement |
  










	
        Compensation Information for Catherine A. Knupp , Executive Vice President and President of R&D of ZOETIS INC | Salary.com
    


























Enterprise
Small Business
Personal




Contact Us
Log In


































Salaries
Jobs
Education
Advice
























 





Catherine A. Knupp 
Executive Compensation
As Executive Vice President and President of R&D at ZOETIS INC, Catherine A. Knupp  made $2,193,230 in total compensation.  Of this total $525,027 was received as a salary, $474,940 was received as a bonus, $366,663 was received in stock options, $733,301 was awarded as stock and $93,299 came from other types of compensation. This information is according to proxy statements filed for the 2016 fiscal year. 


ENTER AN EXECUTIVE OR COMPANY NAME
New Search


Go



The chart on this page features a breakdown of the total annual pay for Catherine A. Knupp ,  Executive Vice President and President of R&D at ZOETIS INC as reported in their proxy statements. 
Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. ZOETIS INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. ZOETIS INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.
Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.
Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.



Other Executives at this Company


Kristin C. Peck 
Clinton A. Lewis Jr.
Juan Ramón Alaix 
Paul S. Herendeen 

Glenn C. David 






Catherine A. Knupp 


Base Pay$525,027
Bonus + Incentive Comp$474,940
Total Cash Compensation$999,967


Stock Award Value$733,301
Option Award Value$366,663
Total Equity$1,099,964



Total Other$93,299



Total Compensation$2,193,230




Browse Executives by First Name
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z


Browse Companies by Company Name
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#



This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement. 
Use of Data / Disclaimer
The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.
What is a proxy statement?
A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.
The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.







    





 

 






     

privacy policy
terms of use
about us
contact us

©  Salary.com. All rights reserved.


US Salaries
Canadian Salaries
Purchase a Salary Report
Salaries by Category
Salaries by Income
Salaries by Industry
Popular Salaries
Negotiation Tips
Benefits Calculator
Search Job Openings
Job Openings by State
Job Openings by Category
Education by Career
Education by Level
Education by Major
Cost of Living Calculator
























 
